Editor's note: Adam Feuerstein will be the featured guest on TSC Live at noon EDT Tuesday, Sept. 29. Send him your questions by: Emailing us at email@example.com; posting them on our Facebook page, facebook.com/thestreet; Tweeting us @thestreet_news with #tsclive; or posting them on the live show page in the comments section. Bookmark the TSC Live page now.
Cytokinetics saw 2.5 million shares change hands Friday, many times greater than the 50-day average daily volume of 418,000 shares, after Briefing.com reported market chatter of a possible deal that would see Amgen acquire the small-cap biotech company.
Volume was greatest during the 2 p.m. EDT hour, when Cytokinetics' stock hit an intraday high of $5.20, close to its 52-week high. Shares were lately up 55 cents, or 12.3%, at $5.03.Cytokinetics has a 45.3 million-share float with a small short interest float of 2.2% as of Aug. 26, according to Yahoo! Finance. Amgen, on the other hand, has a float of one billion and a short interest float of 2.2%. Amgen has a market cap of $61.5 billion, compared to Cytokinetics' $303 million market cap. Cytokinetics shares are poised to finish the week with an advance of more than 25%. On Monday, the stock popped after a Wedbush Morgan analyst increased the firm's price target to $18 from $4, citing the company's focus on drugs that improve muscle function. Investor posts on Internet message boards Friday argued that Cytokinetics is undervalued, given the company's potential when compared to other biotech companies. Others noted that rumors of a partnership with Amgen first popped up a few months earlier. Some traders pointed out that the stock is now only back to trading where it was a year ago. -- Written by Robert Holmes in New York.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV